AcelRx Pharmaceuticals, Inc. (ACRX) Social Stream



AcelRx Pharmaceuticals, Inc. (ACRX): $0.86

0.06 (+7.50%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Featured Post From StockTwits About ACRX

$ACRX Installation well underway, COVID delayed delivery! 65% per DSUVIA/DZUVEO unit cost savings coming soon!

https://ir.acelrx.com/static-files/9447124c-e04f-4ba7-8fb5-b86e5f630b3a
March 15, 2021 - Raffi Asadorian - Chief Financial Officer
"This will have a significant reduction on our unit cost of production and increase our capacity to meet expected demand from the DoD, Zimmer and growth in hospitals and surgery centers.

Importantly, this also clear the path to finalizing discussions on out-licensing DSUVIA or DZUVEO......

Bullish 6/10/21, 06:52 AM ACRX
"This is one of the best values in the stock market now... Commercial Pain Monopoly on the US Military, Dental, Spinal, Plastic Surgery verticals really heating up... Sickle Cell Pain study... Oncology Pain study, Pre/Post Operative Pain Study, Cleveland Clinical Cardiovascular Surgery Pain study... Amazing April 2021 sales (which we do not know the numbers yet), Partnership with Zimmer Biomet... This is easily worth 10+ within a year
HWtrying, published July 26, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!